Hutchmed’s Phase III colorectal cancer trial meets primary endpoint
Fruquintinib’s safety profile in this trial was in line with priorly reported data from trials.

Fruquintinib’s safety profile in this trial was in line with priorly reported data from trials.
The CMAI total score in brexpiprazole group was statistically higher than for those receiving placebo.
Treatment with quizartinib plus chemotherapy offered a 22.4% decline in mortality risk versus standard chemotherapy alone.
The trial will assess the safety and efficacy of anifrolumab versus placebo in adults with active Class III or IV…
In the Phase IIb trial of S-217622 that enrolled 428 patients in Japan and South Korea, no serious safety issues…
Fujifilm attributed the termination of new subject enrolment to the spread of the Omicron variant of the SARS-CoV-2 virus.
The trial will assess the safety and efficacy of the booster vaccine in healthy adult subjects in Japan.
In the trial, 55.7% of patients in the Livtencity arm attained CMV DNA level below the LLOQ by week eight.
Thank you for subscribing to Clinical Trials Arena